Net profit of Bafna Pharmaceuticals rose 93.68% to Rs 1.84 crore in the quarter ended December 2025 as against Rs 0.95 crore during the previous quarter ended December 2024. Sales rose 15.37% to Rs 38.29 crore in the quarter ended December 2025 as against Rs 33.19 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales38.2933.19 15 OPM %7.979.25 - PBDT3.412.62 30 PBT1.840.96 92 NP1.840.95 94 Powered by Capital Market - Live News

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live News

Net profit of Bafna Pharmaceuticals rose 19.08% to Rs 3.12 crore in the quarter ended September 2025 as against Rs 2.62 crore during the previous quarter ended September 2024. Sales declined 12.03% to Rs 35.47 crore in the quarter ended September 2025 as against Rs 40.32 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales35.4740.32 -12 OPM %12.049.42 - PBDT4.594.20 9 PBT3.122.62 19 NP3.122.62 19 Powered by Capital Market - Live News

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live News

Bafna Pharmaceuticals announced that the 30th Annual General Meeting(AGM) of the company will be held on 19 September 2025.Powered by Capital Market - Live News